[MO4] Mini-Oral Session 4　Lung Cancer / Thoracic Cancer 2（Miscellaneous）
【E】

[MO4-1] Management of Infusion-related Reactions in Patients Receiving Amivantamab in the CHRYSALIS Study

^○Keunchil Park¹, Joshua Sabari², Eric B. Haura³, Catherine A. Shu⁴, Alexander Spira⁵, Ravi Salgia⁶, Karen L. Reckamp⁷, Rachel E. Sanborn⁸, Ramaswamy Govindan⁹, Joshua M. Bauml¹⁰, Joshua C. Curtin¹¹, John Xie¹¹, Amy Roshak¹¹, Patricia Lorenzini¹¹, Dawn Millington¹¹, Meena Thayu¹¹, Roland E. Knoblauch¹¹, Byoung Chul Cho¹² (1.Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 2.NYU School of Medicine, 3.H. Lee Moffitt Cancer Center & Research Institute, 4.Columbia University Medical Center, 5.Virginia Cancer Specialists Research Institute, US Oncology Research, 6.City of Hope, 7.Cedars-Sinai Medical Center, 8.Earle A. Chiles Research Institute, Providence Cancer Institute, 9.Washington University School of Medicine, 10.Perelman School of Medicine at the University of Pennsylvania, 11.Janssen R&D, LLC, 12.Yonsei Cancer Center, Yonsei University College of Medicine)